JP2007523631A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523631A5 JP2007523631A5 JP2006541469A JP2006541469A JP2007523631A5 JP 2007523631 A5 JP2007523631 A5 JP 2007523631A5 JP 2006541469 A JP2006541469 A JP 2006541469A JP 2006541469 A JP2006541469 A JP 2006541469A JP 2007523631 A5 JP2007523631 A5 JP 2007523631A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarker
- pancreatic adenocarcinoma
- sample
- subject
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 114
- 239000000090 biomarker Substances 0.000 claims 106
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 93
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 93
- 239000000523 sample Substances 0.000 claims 68
- 230000000694 effects Effects 0.000 claims 59
- 108090000623 proteins and genes Proteins 0.000 claims 52
- 150000001875 compounds Chemical class 0.000 claims 45
- 238000010171 animal model Methods 0.000 claims 42
- 239000000203 mixture Substances 0.000 claims 36
- 102000004169 proteins and genes Human genes 0.000 claims 30
- 238000012360 testing method Methods 0.000 claims 30
- 108091033319 polynucleotide Proteins 0.000 claims 20
- 102000040430 polynucleotide Human genes 0.000 claims 20
- 239000002157 polynucleotide Substances 0.000 claims 20
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 19
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 19
- 230000014509 gene expression Effects 0.000 claims 19
- 102100030708 GTPase KRas Human genes 0.000 claims 12
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 230000003213 activating effect Effects 0.000 claims 12
- 230000035772 mutation Effects 0.000 claims 12
- 239000003153 chemical reaction reagent Substances 0.000 claims 10
- 238000002560 therapeutic procedure Methods 0.000 claims 9
- 241001465754 Metazoa Species 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 238000012423 maintenance Methods 0.000 claims 5
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 claims 4
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 4
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000009396 hybridization Methods 0.000 claims 4
- 238000012544 monitoring process Methods 0.000 claims 4
- 238000006452 multicomponent reaction Methods 0.000 claims 4
- 210000004923 pancreatic tissue Anatomy 0.000 claims 4
- 230000009261 transgenic effect Effects 0.000 claims 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 3
- 101710102803 Tumor suppressor ARF Proteins 0.000 claims 3
- 210000000941 bile Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 230000000711 cancerogenic effect Effects 0.000 claims 3
- 231100000315 carcinogenic Toxicity 0.000 claims 3
- 210000003608 fece Anatomy 0.000 claims 3
- 230000000977 initiatory effect Effects 0.000 claims 3
- 239000002853 nucleic acid probe Substances 0.000 claims 3
- 102200006539 rs121913529 Human genes 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 210000002700 urine Anatomy 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 241000283984 Rodentia Species 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 238000004891 communication Methods 0.000 claims 2
- 230000000052 comparative effect Effects 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 238000011161 development Methods 0.000 claims 2
- 230000018109 developmental process Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 230000002974 pharmacogenomic effect Effects 0.000 claims 2
- 229940124606 potential therapeutic agent Drugs 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 238000003753 real-time PCR Methods 0.000 claims 2
- 230000011218 segmentation Effects 0.000 claims 2
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 101150008921 Brca2 gene Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108700005087 Homeobox Genes Proteins 0.000 claims 1
- 101000733249 Homo sapiens Tumor suppressor ARF Proteins 0.000 claims 1
- -1 Ink4a Proteins 0.000 claims 1
- 101150110531 MLH1 gene Proteins 0.000 claims 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 claims 1
- 101150040067 STK11 gene Proteins 0.000 claims 1
- 102000049937 Smad4 Human genes 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 claims 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000000104 diagnostic biomarker Substances 0.000 claims 1
- 230000002183 duodenal effect Effects 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 238000007901 in situ hybridization Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000000092 prognostic biomarker Substances 0.000 claims 1
- 230000004850 protein–protein interaction Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 238000007423 screening assay Methods 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 239000000225 tumor suppressor protein Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52546403P | 2003-11-26 | 2003-11-26 | |
| US60/525,464 | 2003-11-26 | ||
| PCT/US2004/039756 WO2005053512A2 (en) | 2003-11-26 | 2004-11-24 | Animal models of pancreatic adenocarcinoma and uses therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007523631A JP2007523631A (ja) | 2007-08-23 |
| JP2007523631A5 true JP2007523631A5 (https=) | 2008-01-17 |
| JP4733644B2 JP4733644B2 (ja) | 2011-07-27 |
Family
ID=34652344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541469A Expired - Fee Related JP4733644B2 (ja) | 2003-11-26 | 2004-11-24 | 膵臓腺癌の動物モデルおよびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080242742A1 (https=) |
| EP (1) | EP1718192A4 (https=) |
| JP (1) | JP4733644B2 (https=) |
| CA (1) | CA2547355A1 (https=) |
| WO (1) | WO2005053512A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1774043A4 (en) * | 2004-05-28 | 2009-09-02 | Dana Farber Cancer Inst Inc | COMPOSITIONS, KITS AND METHODS OF IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CANCER |
| CN102203295A (zh) * | 2008-09-03 | 2011-09-28 | 约翰霍普金斯大学 | 胰腺肿瘤发生的通路及遗传性胰腺癌基因 |
| US8420884B2 (en) * | 2008-10-16 | 2013-04-16 | Tufts Medical Center Inc. | Models of malignant brain cancer, and therapeutic siRNAs against oncogenic signaling pathways, and methods and kits for uses therefor |
| WO2010124200A2 (en) * | 2009-04-23 | 2010-10-28 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for cancer |
| EP2481800B1 (en) * | 2009-06-01 | 2018-02-21 | Sungkyunkwan University Foundation For Corporate Collaboration | Nucleic acid aptamer specifically binding to pancreatic cancer cells or tissues and use thereof |
| US10132811B2 (en) * | 2009-06-25 | 2018-11-20 | The Regents Of The University Of California | Salivary transcriptomic and microbial biomarkers for pancreatic cancer |
| EP2449112A1 (en) | 2009-07-01 | 2012-05-09 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for severe combined immunodeficiency (scid) |
| ES2767881T3 (es) * | 2009-08-14 | 2020-06-18 | Revivicor Inc | Cerdos multi-transgénicos para el tratamiento de diabetes |
| MX2013008833A (es) * | 2011-02-02 | 2013-12-06 | Amgen Inc | Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r). |
| RU2457546C1 (ru) * | 2011-03-09 | 2012-07-27 | Учреждение Российской академии медицинских наук Научный центр реконструктивной и восстановительной хирургии Сибирского отделения РАМН (НЦРВХ СО РАМН) | Способ моделирования аденокарциномы толстой кишки человека |
| WO2013039477A1 (en) | 2011-09-12 | 2013-03-21 | University Of South Alabama | Non-invasive methods of detecting target molecules |
| WO2013184905A1 (en) | 2012-06-06 | 2013-12-12 | Myriad Genetics, Inc. | Hereditary cancer genes |
| EP2972375A2 (en) * | 2013-03-13 | 2016-01-20 | Creatics LLC | Methods and compositions for detecting pancreatic cancer |
| HK1220323A1 (zh) * | 2013-03-15 | 2017-05-05 | Exemplar Genetics, Llc | 癌症的动物模型 |
| KR101456627B1 (ko) * | 2013-04-24 | 2014-11-03 | 국립암센터 | 면역 치료 및 위암 치료제에 대한 효능 및 독성 평가를 위한 마우스 위암 세포주 |
| US20150191744A1 (en) | 2013-12-17 | 2015-07-09 | University Of Massachusetts | Cas9 effector-mediated regulation of transcription, differentiation and gene editing/labeling |
| US9986723B2 (en) * | 2014-10-22 | 2018-06-05 | The Board Of Regents Of The University Of Texas System | Screen and use of therapeutics for pancreatic ductal adenocarcinoma |
| JP6695586B2 (ja) * | 2015-12-17 | 2020-05-20 | 国立大学法人北海道大学 | 膵癌の再発リスクの予測に用いるための診断薬及びキット、並びに予測方法 |
| WO2018230970A1 (ko) | 2017-06-14 | 2018-12-20 | 서울대학교 산학협력단 | 돌연변이 마우스 유래 췌장 오거노이드 및 그 용도 |
| EP3890753A4 (en) * | 2018-12-03 | 2023-04-05 | Triplet Therapeutics, Inc. | METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPETITION EXPANSION DISORDERS ASSOCIATED WITH MLH1 ACTIVITY |
| CN114672517B (zh) * | 2020-12-24 | 2024-01-19 | 四川大学华西医院 | 一种全新基因组合模式在小鼠中建立胰腺癌的方法 |
| CN114651786B (zh) * | 2022-04-01 | 2023-05-26 | 广西医科大学 | 一种小鼠马尔尼菲篮状菌潜伏再激活模型的构建方法 |
| CN120843600A (zh) * | 2025-08-08 | 2025-10-28 | 中国医学科学院肿瘤医院 | 一种自发性食管癌前病变或食管癌非人类动物模型的构建方法及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6033862A (en) | 1996-10-30 | 2000-03-07 | Tokuyama Corporation | Marker and immunological reagent for dialysis-related amyloidosis, diabetes mellitus and diabetes mellitus complications |
| US6639121B1 (en) * | 1999-07-29 | 2003-10-28 | Dana-Farber Cancer Institute, Inc. | Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo |
| ATE406094T1 (de) * | 2001-03-28 | 2008-09-15 | Dana Farber Cancer Inst Inc | Identifizierung und charakterisierung von genen |
| AU2003228517B2 (en) * | 2002-04-16 | 2007-06-21 | Dana-Farber Cancer Institute, Inc. | Cancer models |
| AU2004268639B2 (en) * | 2003-08-28 | 2008-10-23 | Aveo Pharmaceuticals, Inc. | Chimeric cancer models |
-
2004
- 2004-11-24 JP JP2006541469A patent/JP4733644B2/ja not_active Expired - Fee Related
- 2004-11-24 WO PCT/US2004/039756 patent/WO2005053512A2/en not_active Ceased
- 2004-11-24 EP EP04812305A patent/EP1718192A4/en not_active Withdrawn
- 2004-11-24 CA CA002547355A patent/CA2547355A1/en not_active Abandoned
-
2006
- 2006-08-11 US US11/503,499 patent/US20080242742A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007523631A5 (https=) | ||
| Amundadottir | Pancreatic cancer genetics | |
| Keng et al. | A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma | |
| Daniotti et al. | BRAF alterations are associated with complex mutational profiles in malignant melanoma | |
| JP2010524427A (ja) | 慢性移植片機能障害のためのバイオマーカー | |
| AU2009270851A1 (en) | Signatures and PCDETERMINANTS associated with prostate cancer and methods of use thereof | |
| US8168602B2 (en) | Compositions, kits and methods for identification, assessment, prevention and therapy of cancer | |
| JP4733644B2 (ja) | 膵臓腺癌の動物モデルおよびその使用 | |
| JP2008512984A5 (https=) | ||
| Yassin et al. | Cytoglobin affects tumorigenesis and the expression of ulcerative colitis-associated genes under chemically induced colitis in mice | |
| Flanagan et al. | Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features | |
| Oh et al. | Single nucleotide polymorphisms of 8 inflammation‐related genes and their associations with smoking‐related cancers | |
| Webster et al. | The tumor suppressor BAP 1 cooperates with BRAFV 600E to promote tumor formation in cutaneous melanoma | |
| JP2007528707A (ja) | 統合失調症の診断および治療のための標的としてのｅｇｒ遺伝子 | |
| Jensen et al. | Genetic control of renal tumorigenesis by the mouse Rtm1 locus | |
| Schoultz et al. | Tissue specificity of oncogenic BRAF targeted to lung and thyroid through a shared lineage factor | |
| Rivas et al. | Transcriptomic and genetic profiling in a spontaneous non-human primate model of hypertrophic cardiomyopathy and sudden cardiac death | |
| JP2004510442A (ja) | 腫瘍マーカーおよび使用方法 | |
| Hodis | The somatic genetics of human melanoma | |
| Poirier et al. | ZNF768 loss amplifies p53 action and reduces lung tumorigenesis in mice | |
| McCaughan et al. | Comprehensive investigation of the caveolin 2 gene: resequencing and association for kidney transplant outcomes | |
| KR102279189B1 (ko) | 대장암의 전이 치료용 약학적 조성물 | |
| US20230383360A1 (en) | Biomarkers for predicting responsiveness to mek inhibitor monotherapy and combination therapy | |
| Raven et al. | Hepatocyte identity and zonal position determine tumourigenic potential of mutant β-catenin | |
| 이광훈 | Adult-Type IDH-Mutant Diffuse Gliomas: A Comprehensive Study of Genetic Landscapes, Methylation Profiling, and Prognostic Markers |